Patient Education
Share your love
Screening for Demodex blepharitis: Integrating best practices into routine eye care | Ophthalmology Times
(Image Credit: AdobeStock) Demodex blepharitis is more common than previously thought, and proper diagnosis and management are important for effective patient care. Anne M. Zaki, MD, a cornea specialist in private practice at Desert Eye Specialists in Peoria, Arizona, moderated…
Dompé enrolls first patients in phase 3 study of isocyclosporin for treatment of atopic keratoconjunctivitis | Ophthalmology Times
(Image Credit: AdobeStock/kerkezz) Biopharmaceutical company Dompé has enrolled the first patients in its phase 3 study of isocyclosporin for the treatment of atopic keratoconjunctivitis (AKC). The multicenter, randomized, double-masked study will compare isocyclosporin against a vehicle control in the improvement…
Seeing the difference: Multimodal imaging for AMD and GA | Ophthalmology Times
(Image Credit: AdobeStock/jtamm) A timely and accurate diagnosis of retinal disease gives patients the best chance of achieving an optimal visual outcome. This is particularly true now, with the availability of drug treatments for geographic atrophy (GA) and inherited retinal…
NCX 470 advances toward US, China NDA submissions for NCX 470 | Ophthalmology Times
(Image Credit: AdobeStock) Nicox has announced it has acquired and analyzed all key data required to support the submission of New Drug Applications (NDAs) in the US and China for NCX 470.1 NCX 470 is Nicox’s lead clinical product candidate…
Unmet Needs in Dry Eye Disease | Ophthalmology Times
The Viewpoints series “Reimagining Dry Eye Management: Targeting Tear Function for Sustained Relief” convenes leading experts in ophthalmology and optometry to discuss evolving perspectives on dry eye disease (DED). Under the moderation of Kendall Donaldson, MD, MS, the panel—comprising Cecelia…
Management and Monitoring Strategies in Dry Eye Disease | Ophthalmology Times
The Viewpoints series “Reimagining Dry Eye Management: Targeting Tear Function for Sustained Relief” convenes leading experts in ophthalmology and optometry to discuss evolving perspectives on dry eye disease (DED). Under the moderation of Kendall Donaldson, MD, MS, the panel—comprising Cecelia…
Malar edema: Perspectives from plastic surgery and ophthalmology | Ophthalmology Times
(Image Credit: AdobeStock/Alessandro Grandini) Malar edema, the collection of fluid below the infraorbital rim and over the malar eminence, presents a unique challenge to providers in aesthetics and ophthalmology.1 Despite their seemingly benign nature, the presence of malar edema or…
Spotlight on women’s health: Understanding thyroid eye disease | Ophthalmology Times
Image by Jennifer Toomey/MJH Life Sciences using AI Thyroid eye disease (TED), also known as Graves ophthalmopathy or Graves eye disease, is an autoimmune condition in which the immune system targets tissues related to the thyroid.1 This leads to inflammation…
FDA extends Aldeyra’s reproxalap PDUFA after requesting additional clinical study report | Ophthalmology Times
(Image Credit: AdobeStock) The US Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) target action date for Aldeyra’s New Drug Application (NDA) for reproxalap for the treatment of dry eye disease (DED). The new…
Enhancing Durability and Fluid Control with Aflibercept 8 mg in Retinal Vascular Diseases | Ophthalmology Times
This discussion centers on real-world comparisons between aflibercept 2 mg and the newer 8 mg formulation, focusing on drying efficacy, durability, and patient experience. Clinicians agree that aflibercept 8 mg offers a clear advantage in retinal fluid control and treatment…